The stock of Sun Pharma is likely to witness buying interest as the company got permission from the US Federal Drug Administration for its Ultram ER tablets, a pain relieving drug. According to a notice issued to the BSE, the company has said that its subsidiary got an approval from the US authority for its abbreviated new drug application to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets. According to the company, Tramadol HCL ER tablets have annual sales of nearly $125 million in the US. Shares of Sun Pharma on Friday closed at Rs 512.40 on the BSE, down 1.19 per cent from its previous day close.

comment COMMENT NOW